A group of researchers from Massachusetts Institute of Technology (MIT) It has developed a new experimental strategy that allows one joint to fight against Arthrosis by accessing the inner cartilage of the joints and regenerating it. This advance tested in rats is one step forward for receiving treatment that slows down the development of a pathogenic disease till date.
Arthrosis is a progressive degeneration of cartilage of joints produced by old age or trauma. The disease affects about 300 million people worldwide, and has no effect against it, because cartilage is a tissue that can not be reproduced. Although there is a cure that can damage the symptoms of osteoarthritis, there is no cure until it can slow down its progress.
One of the remedies for treatment is that medicines can not be easily inserted into therapy. Most joints are removed before being affected or do not enter the inner part of the cartilage, where the cells that produce it are found, so that they can not handle their functions.
Therefore, researchers have created a nanocarse, an atom that acts as a vehicle that acts as a vehicle and takes a drug in condocites. This piazone consists of a circular portion, in which the drug builds, the positive electrical charge is combined with branch-like structures and the PEG.
Because there is a negative charge in the cartilage, the positive charge of the nontransporter adheres to the tissues. On the other hand, PEG allows to open the road through cartilage and thus it reaches the condors.
According to the magazine Science Translational MedicineScientists have added INF-1 to a nanocorier drug, in which cartilage production is a stimulus and the task of promoting the development and development of tonochocites. In order to test this experiment, the nanocarrier was given injection of the knee joints in which the osteoarthritis was from the injury.
This treatment reduced the appearance of cartilage degradation, inflammation and bone changes. Likewise, with nanocarrier, half of the drug's life in the joints is multiplied by ten. In addition, this therapy was kept in an effective concentration for thirty days, so potentially a bilateral or monthly injection would be sufficient.
According to the International Osteoarthritis Foundation (OAFI) therapist and president Joseph Varages, "It is a very interesting study, which is not involved in research.
According to verges, if it is applied to people and it is effective in rats, it can improve the quality of patients' lives, because it will be enough with one or two injections every month. However, it is still necessary to see if it is confirmed in clinical trials. It adds that it can take about four to eight years for the drug to become commercially available.